Detalhe da pesquisa
1.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Haematologica
; 109(3): 867-876, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646657
2.
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Ann Hematol
; 102(6): 1501-1511, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37088816
3.
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Br J Haematol
; 196(4): 954-962, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34726261
4.
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Neoplasma
; 69(6): 1474-1479, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36591805
5.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
BMC Cancer
; 21(1): 73, 2021 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451293
6.
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Eur J Haematol
; 107(4): 466-474, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272773
7.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769076
8.
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Br J Haematol
; 190(2): 189-197, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32163180
9.
[Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients]. / Transplantace srdce a následující lécba AL-amyloidózy u 5 pacientu.
Vnitr Lek
; 64(4): 441-449, 2018.
Artigo
em Cs
| MEDLINE | ID: mdl-29791180
10.
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Eur J Haematol
; 99(1): 80-90, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28384387
11.
[Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks]. / Osteoprotektivní lécba bisfosfonáty nebo denosumabem u nemocných s mnohocetným myelomem: prínos a rizika.
Vnitr Lek
; 63(5): 311-321, 2017.
Artigo
em Cs
| MEDLINE | ID: mdl-28726429
12.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol
; 17(1): 27-38, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26671818
13.
Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Eur J Haematol
; 96(2): 119-27, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25816709
14.
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
Clin Lymphoma Myeloma Leuk
; 23(2): 145-153, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36567210
15.
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.
Biomedicines
; 10(10)2022 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36289797
16.
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Cancers (Basel)
; 14(20)2022 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291949
17.
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Ann Hematol
; 90(12): 1441-7, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21380511
18.
Characterisation of trehalose-6-phosphate phosphatases from bacterial pathogens.
Biochim Biophys Acta Proteins Proteom
; 1869(2): 140564, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33171283
19.
Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities.
Cell Rep
; 35(7): 109126, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33974846
20.
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2.
Science
; 369(6508): 1249-1255, 2020 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32680882